✦ LIBER ✦

A phase I clinical and pharmacological profile of dacarbazine with autologous bone marrow transplantation in patients with solid tumors

✍ Scribed by Douglas R. Adkins; Rebecca Irvin; John Kuhn; David H. Boldt; G. David Roodman; Donna Salzman; Cesar Freytes; D. D. Hoff; C. F. LeMaistre

Publisher: Springer US
Year: 1993
Tongue: English
Weight: 873 KB
Volume: 11
Category: Article
ISSN: 0167-6997
DOI: 10.1007/bf00874151

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

High-dose combination chemotherapy with

High-dose combination chemotherapy with autologous bone marrow transplantation in adult solid tumors

✍ Gary Spitzer; Karel A. Dicke; Joe Litam; D. S. Verma; Axel Zander; Victor Lanzot 📂 Article 📅 1980 🏛 John Wiley and Sons 🌐 English ⚖ 931 KB

Autologous bone marrow transplantation i

Autologous bone marrow transplantation in the treatment of children and adolescents with advanced malignant tumors

✍ Baumgartner, Christoph ;Bleher, E. Arnold ;del Re, Guido Brun ;Bucher, Urs ;Deub 📂 Article 📅 1984 🏛 John Wiley and Sons 🌐 English ⚖ 751 KB

Nineteen patients with advanced malignant tumors, less than 20 years old were treated with intensive chemotherapy (vincristine 2 mg/m2 i.v. and adriamycin 60 mg/m2 i.v. on day - 7; cyclophosphamide 45 mg/kg i.v. on days -6 to -3), total body irradiation (TBI, 600 rads on day -1) and autologous bone

Phase I clinical trial of bortezomib in

Phase I clinical trial of bortezomib in combination with gemcitabine in patients with advanced solid tumors

✍ David P. Ryan; Leonard J. Appleman; Thomas Lynch; Jeffrey G. Supko; Panagiotis F 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 114 KB 👁 2 views

## Abstract ## BACKGROUND. Bortezomib is the first proteasome inhibitor to show preliminary evidence of activity against solid tumors. Findings from preclinical studies prompted a Phase I trial to determine the maximum tolerated dose (MTD) and dose‐limiting toxicities (DLTs) of bortezomib in combi

Phase I clinical trial of weekly combine

Phase I clinical trial of weekly combined paclitaxel plus docetaxel in patients with solid tumors

✍ Jacob Lokich 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 70 KB 👁 2 views

A Phase I and feasibility study of combined docetaxel (D) plus paclitaxel (P) was undertaken to determine the maximum tolerated dose (MTD) and dose-limiting toxicity (DLT) for each analogue delivered concomitantly on a weekly schedule. ## METHODS. Patients were accrued in 3-6 patient cohorts to P

High-dose melphalan, vincristine, and to

High-dose melphalan, vincristine, and total-body irradiation with autologous bone marrow transplantation in children with relapsed neuroblastoma: A phase II study

✍ Pinkerton, C. R. ;Philip, T. ;Biron, P. ;Frapazz, D. ;Phillipe, N. ;Zucker, J. M 📂 Article 📅 1987 🏛 John Wiley and Sons 🌐 English ⚖ 432 KB

Seven children with neuroblastoma who had relapsed on or after conventional therapy (3 originally stage IV, 3 stage III, 1 stage II) were entered on a study of "massive therapy" with purged autologous bone marrow rescue. In 5 patients attempts were made to reinduce remission with alternative chemoth

A phase I study of gemcitabine and docet

A phase I study of gemcitabine and docetaxel in patients with metastatic solid tumors

✍ David P. Ryan; Thomas J. Lynch; Michael L. Grossbard; Michael V. Seiden; Charles 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 70 KB 👁 2 views

A Phase I study was initiated to determine the maximum tolerated dose of weekly gemcitabine combined with monthly, fixed-dose docetaxel. ## METHODS. Patients with metastatic solid tumors were treated with docetaxel, 60 mg/m 2 , on Day 1 every 28 days. Gemcitabine was administered on Days 1, 8, and